Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 7
2005 6
2006 10
2007 9
2008 9
2009 14
2010 7
2011 15
2012 14
2013 16
2014 14
2015 10
2016 14
2017 22
2018 13
2019 19
2020 33
2021 32
2022 31
2023 21

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
Why does obesity cause diabetes?
Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Klein S, et al. Among authors: gastaldelli a. Cell Metab. 2022 Jan 4;34(1):11-20. doi: 10.1016/j.cmet.2021.12.012. Cell Metab. 2022. PMID: 34986330 Free PMC article. Review.
Insulin: The master regulator of glucose metabolism.
Norton L, Shannon C, Gastaldelli A, DeFronzo RA. Norton L, et al. Among authors: gastaldelli a. Metabolism. 2022 Apr;129:155142. doi: 10.1016/j.metabol.2022.155142. Epub 2022 Jan 20. Metabolism. 2022. PMID: 35066003 Review.
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.
Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Masoodi M, et al. Among authors: gastaldelli a. Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):835-856. doi: 10.1038/s41575-021-00502-9. Epub 2021 Sep 10. Nat Rev Gastroenterol Hepatol. 2021. PMID: 34508238 Review.
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). European Association for the Study of the Liver (EASL), et al. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7. J Hepatol. 2016. PMID: 27062661 No abstract available.
A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne C, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer D, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot B, Korenjak M, Kowdley K, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell E, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wai-Sun Wong V, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. J Hepatol. 2023 Jun 20:S0168-8278(23)00418-X. doi: 10.1016/j.jhep.2023.06.003. Online ahead of print. J Hepatol. 2023. PMID: 37364790 Free article. Review.
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.
Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Svegliati-Baroni G, et al. Among authors: gastaldelli a. Int J Mol Sci. 2020 Aug 13;21(16):5820. doi: 10.3390/ijms21165820. Int J Mol Sci. 2020. PMID: 32823659 Free PMC article. Review.
Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Méndez-Sánchez N, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248211 No abstract available.
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupșor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yılmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Mózes FE, et al. Gut. 2022 May;71(5):1006-1019. doi: 10.1136/gutjnl-2021-324243. Epub 2021 May 17. Gut. 2022. PMID: 34001645 Free PMC article.
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Gastaldelli A, et al. Lancet Diabetes Endocrinol. 2022 Jun;10(6):393-406. doi: 10.1016/S2213-8587(22)00070-5. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468325 Clinical Trial.
276 results